Literature DB >> 9188615

The herpes simplex virus type 1 latency-associated transcript gene regulates the establishment of latency.

R L Thompson1, N M Sawtell.   

Abstract

Herpes simplex virus type 1 establishes latent infections in sensory neurons. During latency only one locus, the latency-associated transcript (LAT), is abundantly transcribed. Several lines of evidence suggest that this locus is required for the efficient reactivation from latency in experimental models. However, it is not yet clear whether this is a direct effect on the reactivation process per se or, as we have suggested, an indirect effect resulting from a decreased efficiency of establishment of latent infections. In this report wild-type and genetically engineered viral mutants were analyzed in a mouse model using a recently developed approach to precisely quantify latently infected neurons. It was found that strain KOS/M established latent infections, as defined by the presence of the viral genome, in about 30% of the neurons. Thirty-three percent of the mice with this latent viral burden reactivated in vivo following hyperthermic stress. In contrast, mutants in which either the basal LAT promoter or the 5' end of the LAT gene was deleted established latency in only 10% of trigeminal neurons (P < 0.00001), and these mice were impaired for reactivation. Repair of the locus resulted in wild-type levels of establishment and reactivation, mapping this function to the LAT region. Finer mapping demonstrated that a 2.3-kb fragment that contains the major LAT transcripts was sufficient to promote efficient establishment and subsequent reactivation when expressed in the context of a foreign gene. Hyperthermic stress applied during the first 3 days postinfection resulted in greatly increased numbers of neurons harboring the latent viral genome. This approach was found to increase the level of establishment of LAT-null mutants to that normally achieved by wild-type KOS/M. These establishment-repaired mice reactivated with wild-type efficiency. Thus, the LAT gene serves to increase the number of neurons in which latency is established, and no direct role for the LAT locus in reactivation could be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9188615      PMCID: PMC191783          DOI: 10.1128/JVI.71.7.5432-5440.1997

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  An HSV-1 mutant lacking the LAT TATA element reactivates normally in explant cocultivation.

Authors:  S L Deshmane; M Nicosia; T Valyi-Nagy; L T Feldman; A Dillner; N W Fraser
Journal:  Virology       Date:  1993-10       Impact factor: 3.616

2.  Quantification of transcripts from the ICP4 and thymidine kinase genes in mouse ganglia latently infected with herpes simplex virus.

Authors:  M F Kramer; D M Coen
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

3.  The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency.

Authors:  G C Perng; E C Dunkel; P A Geary; S M Slanina; H Ghiasi; R Kaiwar; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

4.  Herpes simplex virus type 1 DNA replication and gene expression during explant-induced reactivation of latently infected murine sensory ganglia.

Authors:  G B Devi-Rao; D C Bloom; J G Stevens; E K Wagner
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

5.  Latent infection can be established with drastically restricted transcription and replication of the HSV-1 genome.

Authors:  F Sedarati; T P Margolis; J G Stevens
Journal:  Virology       Date:  1993-02       Impact factor: 3.616

6.  Neurons containing latency-associated transcripts are numerous and widespread in dorsal root ganglia following footpad inoculation of mice with herpes simplex virus type 1 mutant in1814.

Authors:  M S Ecob-Prince; C M Preston; F J Rixon; K Hassan; P G Kennedy
Journal:  J Gen Virol       Date:  1993-06       Impact factor: 3.891

7.  The spontaneous reactivation function of the herpes simplex virus type 1 LAT gene resides completely within the first 1.5 kilobases of the 8.3-kilobase primary transcript.

Authors:  G C Perng; H Ghiasi; S M Slanina; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

8.  In situ DNA PCR and RNA hybridization detection of herpes simplex virus sequences in trigeminal ganglia of latently infected mice.

Authors:  A Mehta; J Maggioncalda; O Bagasra; S Thikkavarapu; P Saikumari; T Valyi-Nagy; N W Fraser; T M Block
Journal:  Virology       Date:  1995-01-10       Impact factor: 3.616

9.  Expression of a putative ATPase suppresses the growth defect of a yeast potassium transport mutant: identification of a mammalian member of the Clp/HSP104 family.

Authors:  F Périer; C M Radeke; K F Raab-Graham; C A Vandenberg
Journal:  Gene       Date:  1995-01-23       Impact factor: 3.688

10.  Two herpes simplex virus type 1 latency-active promoters differ in their contributions to latency-associated transcript expression during lytic and latent infections.

Authors:  X Chen; M C Schmidt; W F Goins; J C Glorioso
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

View more
  111 in total

1.  Enhancer and long-term expression functions of herpes simplex virus type 1 latency-associated promoter are both located in the same region.

Authors:  H Berthomme; J Thomas; P Texier; A Epstein; L T Feldman
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection.

Authors:  X J Da Costa; C A Jones; D M Knipe
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

3.  The stable 2.0-kilobase intron of the herpes simplex virus type 1 latency-associated transcript does not function as an antisense repressor of ICP0 in nonneuronal cells.

Authors:  Edward A Burton; Chang-Sook Hong; Joseph C Glorioso
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 4.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part I. HSV-1 structure, replication and pathogenesis.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

5.  The relationship of herpes simplex virus latency associated transcript expression to genome copy number: a quantitative study using laser capture microdissection.

Authors:  Xiao-Ping Chen; Marina Mata; Mary Kelley; Joseph C Glorioso; David J Fink
Journal:  J Neurovirol       Date:  2002-06       Impact factor: 2.643

Review 6.  Herpes simplex virus latency-associated transcript gene function.

Authors:  Jennifer R Kent; Wen Kang; Cathie G Miller; Nigel W Fraser
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

7.  Quantitative analysis of herpes simplex virus reactivation in vivo demonstrates that reactivation in the nervous system is not inhibited at early times postinoculation.

Authors:  N M Sawtell
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

8.  Analysis of herpes simplex virus ICP0 promoter function in sensory neurons during acute infection, establishment of latency, and reactivation in vivo.

Authors:  R L Thompson; May T Shieh; N M Sawtell
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Deletion of Herpes Simplex Virus 1 MicroRNAs miR-H1 and miR-H6 Impairs Reactivation.

Authors:  Enrico R Barrozo; Sanae Nakayama; Pankaj Singh; Emilia A H Vanni; Ann M Arvin; Donna M Neumann; David C Bloom
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

10.  Herpes Simplex Virus 2 Latency-Associated Transcript (LAT) Region Mutations Do Not Identify a Role for LAT-Associated MicroRNAs in Viral Reactivation in Guinea Pig Genital Models.

Authors:  Yoshiki Kawamura; Marta Bosch-Marce; Shuang Tang; Amita Patel; Philip R Krause
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.